Forum Topic Cardiovascular
  • Conversation: Brilinta/Brilique (ticagrelor) - mechanism of action - AstraZeneca

    • April 19, 2018 2:01 PM BST
    • Brilinta/Brilique (ticagrelor) - mechanism of action - AstraZeneca

      Brilique is an oral antiplatelet treatment for acute coronary syndrome (ACS). Brilique is a direct-acting P2Y12 receptor antagonist in a chemical class called cyclo-pentyl-triazolo-pyrimidines (CPTPs). Brilique works by inhibiting platelet activation and has been shown to reduce the rate of thrombotic CV events, such as a heart attack or CV death, in patients with ACS.

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
‚Äč